U.S. researchers said genetic testing could have aided in identifying patients who would become depressed or commit suicide while taking Sanofi-Aventis' weight-loss drug Acomplia in a 2008 study, which led to the product's withdrawal from the European market. "Genomics could potentially be used to pre-empt use of the drug in individuals with risk of serious adverse events," the lead author said.

Full Story:

Related Summaries